# Nu-Med Plus, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Nu-Med Plus, Inc.). ## Overview Nu-Med Plus, Inc. is a U.S.-based medical device company focused on developing nitric oxide technologies for hospital, clinical, research, and mobile delivery applications. The company was formed to design, manufacture, and market nitric oxide generating formulations and delivery systems for use in medical procedures and related laboratory settings. ## Products & services • Nitric oxide generating compound formulation • Hospital bedside nitric oxide delivery system • Clinical nitric oxide delivery system • Mobile rechargeable nitric oxide gas device • Nitric oxide system for research applications - **Nitric oxide formulations** (20%) — Compound-based technologies designed to generate nitric oxide for medical and research use. - **Hospital delivery systems** (25%) — Bedside nitric oxide delivery systems intended for hospital use in clinical care settings. - **Clinical and rehabilitation devices** (25%) — Portable or clinic-based nitric oxide delivery units for medical clinics and rehabilitation centers. - **Mobile nitric oxide devices** (15%) — Rechargeable mobile devices designed to deliver nitric oxide gas outside fixed hospital settings. - **Research systems** (15%) — Nitric oxide systems used for non-clinical laboratory and research applications. - Nitric oxide generating compound formulation - Hospital bedside nitric oxide delivery system - Clinical nitric oxide delivery system - Mobile rechargeable nitric oxide gas device - Nitric oxide system for research applications ## Customers Nu-Med Plus targets hospitals, health systems, clinics, rehabilitation centers, and medical professionals that use nitric oxide in patient care. It also addresses research and laboratory users that need nitric oxide systems for non-clinical applications. The company’s products are aimed at buyers seeking specialized delivery technologies for defined medical procedures and use cases. - **Hospitals and health systems** (primary) — Buy bedside nitric oxide delivery systems for inpatient clinical use and procedure support. - **Clinics and rehabilitation centers** (secondary) — Buy clinical nitric oxide units for outpatient or specialty care settings. - **Research laboratories** (secondary) — Buy nitric oxide systems for non-clinical laboratory and research applications. - **Medical professionals** (secondary) — Influence adoption by specifying devices that address a defined procedural need. - **International distributors and users** (emerging) — Potential buyers of early non-medical or lab-use units outside the U.S. approval pathway. - Hospitals and health systems using bedside nitric oxide delivery - Clinics and rehabilitation centers needing portable treatment devices - Medical professionals seeking specialized nitric oxide systems - Research and laboratory users for non-clinical nitric oxide work - International buyers for early non-medical or lab equipment sales ## Geography Nu-Med Plus is headquartered in Port Jefferson, New York and was incorporated in Utah. Its products are intended for use in the United States and in international markets, but human medical sales depend on regulatory approval in each jurisdiction. Geography matters because the company’s addressable market is shaped by FDA and foreign agency requirements for nitric oxide devices. - Headquartered in Port Jefferson, New York - Incorporated in Utah - U.S. market requires FDA approval for human medical use - International sales depend on local medical device approvals - Non-clinical research units may be sold earlier than medical devices ## Strategy The company’s strategy is to develop nitric oxide technologies that address specific medical needs and then commercialize them across hospital, clinic, research, and mobile-use settings. It also appears to pursue early non-clinical or laboratory sales as a bridge toward broader medical adoption, while keeping the core focus on FDA-regulated human-use devices. - **Advance nitric oxide device development** (medium-term) — Product development is the basis for future commercialization and market entry. - **Secure regulatory approvals** (medium-term) — Human medical use in the U.S. and abroad requires FDA and foreign agency clearance. - **Commercialize research and lab-use units** (short-term) — Earlier non-clinical sales could create initial market presence before medical approval. - Develop nitric oxide devices for defined medical use cases - Target niche applications with clear clinical demand - Pursue non-clinical laboratory sales before full medical approval - Build a pathway from research systems to hospital and clinic devices - Seek international commercialization alongside U.S. approval efforts ## Risks Nu-Med Plus faces development, regulatory, and financing risk because its products require substantial testing and approval before human medical sales can begin. As an early-stage medical device company with no revenue disclosed, it is also exposed to customer adoption risk, supplier dependence, and the need for additional capital to continue operations. - **Regulatory approval risk** [critical] — Human medical use of nitric oxide devices requires FDA and foreign agency approval before sales. - **Financing and going-concern risk** [critical] — The company has no revenue disclosed and depends on capital infusions to fund development and operations. - **Development and commercialization risk** [high] — Devices may not reach market acceptance or may take longer and cost more than expected to develop. - **Customer adoption risk** [medium] — Hospitals and clinicians may be slow to adopt a new nitric oxide platform versus existing alternatives. - **Credit risk on receivables** [low] — If sales begin, the company may need allowances for doubtful accounts when customers delay payment. - FDA and foreign approvals may be delayed or denied - No revenue increases dependence on external financing - Product development can stall without capital infusion - Customer credit risk matters if receivables are later generated - Medical device adoption depends on clinical acceptance and reimbursement ## Accounting The main accounting issues are revenue recognition timing, allowance for doubtful accounts, and estimates tied to an early-stage business with limited operating history. Because the company currently reports no revenue, future results will depend heavily on when sales begin, whether they are recognized at a point in time or over time, and how management estimates collectability and development-related costs. - **Revenue recognition** — Will affect reported sales timing once commercialization starts - **Allowance for doubtful accounts** — Could affect net revenue and operating results - **Income taxes and deferred tax assets** — Could affect balance sheet assets and tax expense - Revenue recognition under ASC 606 will matter once sales begin - Allowance for doubtful accounts depends on customer payment behavior - Early-stage estimates may change materially as operations develop - Tax accounting reflects deferred tax asset realization judgments - Future product sales may involve approval-related timing and cutoffs --- *Last updated: 2026-04-29T04:42:06.297711+00:00*